Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aethlon Medical (AEMD) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Aethlon Medical (AEMD) over the last 15 years, with Q1 2025 value amounting to $2.4 million.

  • Aethlon Medical's Cash from Financing Activities rose 544134.17% to $2.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was $7.7 million, marking a year-over-year increase of 50013.62%. This contributed to the annual value of $7.7 million for FY2025, which is 50013.62% up from last year.
  • As of Q1 2025, Aethlon Medical's Cash from Financing Activities stood at $2.4 million, which was up 544134.17% from -$7073.0 recorded in Q4 2024.
  • Aethlon Medical's 5-year Cash from Financing Activities high stood at $17.4 million for Q2 2021, and its period low was -$28134.0 during Q3 2021.
  • Moreover, its 5-year median value for Cash from Financing Activities was -$1884.0 (2022), whereas its average is $2.1 million.
  • As far as peak fluctuations go, Aethlon Medical's Cash from Financing Activities skyrocketed by 2960094.55% in 2022, and later tumbled by 10399.31% in 2024.
  • Over the past 5 years, Aethlon Medical's Cash from Financing Activities (Quarter) stood at -$13557.0 in 2021, then skyrocketed by 86.1% to -$1884.0 in 2022, then skyrocketed by 9501.75% to $177129.0 in 2023, then crashed by 103.99% to -$7073.0 in 2024, then surged by 33453.03% to $2.4 million in 2025.
  • Its Cash from Financing Activities stands at $2.4 million for Q1 2025, versus -$7073.0 for Q4 2024 and -$3832.0 for Q3 2024.